NeuroOne Medical Technologies Overview
Valuation check: NMTC's ROE is -189.76%, below the sector sector average of -5.84%.
Get informed when a big investor buys or sells
+ Follow-189.76%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
NeuroOne Medical Technologies (NMTC) currently reports a ROE of -189.76%. That is below the sector sector average of -5.84%. Use the charts on this page to explore NeuroOne Medical Technologies's ROE history and peer comparisons.
NeuroOne Medical Technologies's ROE of -189.76% is lower than the its sector sector average of -5.84%. That is roughly 3146.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but NeuroOne Medical Technologies's current -189.76% should be judged against industry norms (sector average: -5.84%) and against NMTC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -189.76%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -5.84%. From there, open related valuation or income-statement pages for NeuroOne Medical Technologies, and consider following NMTC for alerts when major investors trade the stock.
